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Abstract
Background: Implantation and growth of metastatic cancer cells at distant organs is promoted by inflammation-
dependent mechanisms. A hepatic melanoma metastasis model where a majority of metastases are generated via
interleukin-18-dependent mechanisms was used to test whether anti-inflammatory properties of resveratrol can
interfere with mechanisms of metastasis.
Methods: Two experimental treatment schedules were used: 1) Mice received one daily oral dose of 1 mg/kg
resveratrol after cancer cell injection and the metastasis number and volume were determined on day 12. 2) Mice
received one daily oral dose of 1 mg/kg resveratrol along the 5 days prior to the injection of cancer cells and both
interleukin-18 (IL-18) concentration in the hepatic blood and microvascular retention of luciferase-transfected B16M
cells were determined on the 18th hour. In vitro, primary cultured hepatic sinusoidal endothelial cells were treated
with B16M-conditioned medium to mimic their in vivo activation by tumor-derived factors and the effect of
resveratrol on IL-18 secretion, on vascular cell adhesion molecule-1 (VCAM-1) expression and on tumor cell
adhesion were studied. The effect of resveratrol on melanoma cell activation by IL-18 was also studied.
Results: Resveratrol remarkably inhibited hepatic retention and metastatic growth of melanoma cells by 50% and
75%, respectively. The mechanism involved IL-18 blockade at three levels: First, resveratrol prevented IL-18
augmentation in the blood of melanoma cell-infiltrated livers. Second, resveratrol inhibited IL-18-dependent
expression of VCAM-1 by tumor-activated hepatic sinusoidal endothelium, preventing melanoma cell adhesion to
the microvasculature. Third, resveratrol inhibited adhesion- and proliferation-stimulating effects of IL-18 on
metastatic melanoma cells through hydrogen peroxide-dependent nuclear factor-kappaB translocation blockade on
these cells.
Conclusions: These results demonstrate multiple sites for therapeutic intervention using resveratrol within the
prometastatic microenvironment generated by tumor-induced hepatic IL-18, and suggest a remarkable effect of
resveratrol in the prevention of inflammation-dependent melanoma metastasis in the liver.
Background
Individuals at high risk of metastasis from malignant
tumors are a large group of patients that still does not
receive an efficient treatment. The development of low-
toxicity drugs that target molecular mechanisms pro-
moting intravascular dissemination, microvascular arrest,
and micrometastatic growth of cancer cells is becoming
a feasible strategy to prevent adverse clinical effects of
the metastatic disease in cancer patients. Because
inflammation and oxidative stress have prometastatic
implications at these subclinical stages of metastasis
inception [1,2], agents that target specific genes and
molecules that regulate these host responses to tumor-
derived factors may become good anti-metastatic candi-
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Resveratrol (RVL) –a phytopolyphenol that occurs in
grapes and various other fruits and medicinal plants
[3]– is a broad-spectrum anti-oxidant that inhibits the
experimental development of several cancer types at
diverse stages, metastasis included [4-5, for review see
6], and at relatively non-toxic doses. Not surprisingly,
the effects exerted by RVL are consistent with its capa-
city to interact with molecular targets that are relevant
during carcinogenesis, but also during metastasis. Speci-
fically, RVL inhibits STAT3 and NF-kappaB-dependent
transcription [6,7], Bcl-xL expression [8] and hypoxia-
induced HIF-1alpha and VEGF [9], while it activates
p53 [10] and TRAIL expression [11]. Moreover, nitric
oxide initiates the progression of human melanoma via
a feedback loop involving the apurinic/apyrimidinic
endonuclease-1/redox factor-1, which is also inhibited
by RVL [12]. However, much work needs to be done for
a more complete understanding of its mechanisms of
action and therefore, for a better assessment of its anti-
tumor efficacy.
The experimental hepatic colonization of B16 mela-
noma (B16M) is a unique model for determining thera-
peutic intervention sites of natural antioxidant products,
such as RVL, in the prometastatic microenvironment
created in the liver by tumor-induced microvascular
inflammation. Intrasplenic and left-cardiac ventricle
B16M cell injection routes are followed by formation of
hepatic metastases, the majority of which are proinflam-
matory-cytokine dependent, as shown in IL-1beta- and
IL-1 converting enzyme-deficient mice [13], and with
recombinant IL-1 receptor antagonist [14] and IL-18
binding protein treatments [15]. Consistent with mela-
noma metastasis regulation by proinflammatory cyto-
kines, response of primary cultured hepatic sinusoidal
endothelium (HSE) to B16M cell soluble factors remark-
ably increased cancer cell adherence to tumor-activated
endothelium. This is due to a sequential process invol-
ving TNF-alpha-dependent IL-1beta, which in turn
induced IL-18 to upregulate VCAM-1 via hydrogen per-
oxide (H2O2) [16]. Moreover, blockade of VCAM-1 with
specific antibodies prior to B16M cell injection signifi-
cantly decreased hepatic retention of B16M cells and
metastasis development [17]. Because VCAM-1 expres-
sion is oxidative stress-inducible, in vivo administration
of recombinant catalase resulted in a complete abroga-
tion of both enhanced VCAM-1 expression by HSE cells
obtained from tumor-injected mice and increased B16M
cell adhesion to those HSE [16]. The pivotal position of
H2O2 in this metastasis model was further supported by
the fact that incubation of HSE cells with non-toxic
concentrations of H2O2 also directly enhanced in vitro
VCAM-1-dependent B16M cell adhesion without
inflammatory cytokine mediation [16]. B16M cells also
responded to hepatic-derived IL-18 by enhanced
proliferation [15] and increased adhesion to HSE via a
VLA-4-dependent mechanism [17].
In this study, we investigated the effect of RVL on the
microvascular phase of the hepatic metastasis process of
B16M cells. First, the effects of RVL on the capillary
arrest and early metastatic growth of intrasplenically-
injected B16M cells were studied in vivo. Second,
because IL-18 regulates melanoma metastasis occur-
rence via VLA-4-dependent B16M cell adhesion to HSE,
the effects of RVL on IL-18 secretion and VCAM-1
expression by hepatic sinusoidal cells, and on the cancer
cell response to IL-18 were studied in vitro.
Our results showed that RVL remarkably inhibited
both hepatic microvascular retention and metastatic
development of B16M cells. In vitro, RVL completely
abrogated the melanoma cell adhesion to tumor-acti-
vated HSE operated via VLA-4/VCAM-1 interaction.
Our results also showed that the antimetastatic effect of
RVL was exerted in this model through an efficient
blockade of IL-18 effects, which was secreted by tumor-
activated hepatic tissue and promoted VLA-4-dependent
melanoma cell adhesion and proliferation via hydrogen
peroxide-dependent NFkappaB activation. These find-
ings suggest that RVL can act as a powerful inhibitor in
the prometastatic microenvironment of hepatic inflam-
mation generated by tumor-induced host IL-18.
Materials and methods
Cells and culture conditions
B16M cells (B16F10 subline) were cultured in DMEM
supplemented with 10% FCS and penicillin-streptomycin
(Sigma Chemicals Co., St. Louis, MO) [10]. B16M-con-
ditioned medium (B16M-CM) was obtained from sub-
confluent cells cultured for 12 hours as previously
described [13].
Hepatic metastasis model and treatment schedule
Syngeneic C57BL/6J mice (male, 6-8 weeks old) were
obtained from IFFA Credo (L’Arbreole, France). Animal
housing, care, and experimental conditions were con-
ducted in conformity with institutional guidelines, in
compliance with the relevant national and international
laws and policies. Hepatic metastases were produced by
intrasplenic injection of B16 cells as previously described
[14]. Mice were killed on the twelfth day afterwards.
Liver tissue was processed for histology [14]. Fifteen 4
μm-thick tissue sections of formaldehyde-fixed liver (five
groups, separated 500 μm) were stained with H&E. An
integrated image analysis system (Olympus Microimage
4.0 capture kit) connected to an Olympus BX51TF
microscope was used to quantify the number, average
diameter, and position coordinates of metastases. Per-
centage of liver volume occupied by metastases and
metastasis density (foci number/100 mm3) were also
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determined [14]. In order to study the effect of RVL
(Sigma-Aldrich Chemicals Co, St Louis, MO) on hepatic
metastasis development, some mice (10 per group)
received 1 mg/kg/day RVL dissolved in ethanol (5%), via
intragastric tube, from day 1 to 12. Control mice
received the same volume of vehicle. Each experiment
was carried out three times.
Quantitative assay on hepatic retention of circulating
melanoma cells
B16M cells were stably transfected with a construct con-
taining the Photinus pyralis luciferase gene coding
sequence under transcriptional control of the cytomega-
lovirus promoter and the neomycin resistance gene [16].
Three hundred thousand viable luciferase-transfected
B16M cells were intrasplenically injected into C57BL/6J
mice (n = 30). Some mice received 1 mg/kg/day RVL
five days prior to B16M-Luc cell injection. All mice
were killed 18 hours later, and livers were analyzed for
luciferase activity (Promega Co., Madison, WI) as
described previously [16].
Isolation of hepatic sinusoidal cells and enriched primary
culture of endothelial cells
HSE cells were isolated from syngeneic C57BL/6J mice
(male, 6-8 weeks old) identified, and cultured as
described previously [16]. Briefly, isolated mouse liver
cells were obtained by two-step collagenase perfusion. A
non-parenchymal liver cell fraction was further purified
by centrifugation in a Percoll® gradient (Amersham;
Uppsala, Sweden). Kupffer cells were then removed by
selective adherence to plastic substrate, HSE cells were
phenotypically characterized by flow cytometry analysis
with specific antibodies against CD31 (PECAM-1 Sigma,
St Louis), HLA class II and CD40, (both from BD Bios-
ciences); CD106 (VCAM-1) and CD14 (both fromBD
Pharmingen, San Diego, CA), smooth muscle alpha
actin (ASMA, Sigma-Aldrich, St Louis, MO). HSE cells
were seeded at 2 × 105 cells/well in RPMI-1640 culture
medium (Sigma Chemicals, St. Louis, MO) supplemen-
ted with 10% FCS (Life Technologies, Gaithersburg,
MD) onto 24-well tissue culture plates pre-coated with
type I collagen solution (0.03 mg/ml) (Collagen Bioma-
terials, Palo Alto, CA) and allowed to spread for 45 min
at 37°C and 5% CO2.
Enzyme immunoassay of IL-18 concentration in hepatic
blood and supernatants of cultured cells
Serum samples were obtained from hepatic (suprahepatic
vein) blood of adult male C57/B1/6J mice 18 hours after
intrasplenic injection of B16M cells. Some mice received
(1 mg/kg/day) RVL from day 1 to 5 via intragastric tube
prior to melanoma cells injection. Primary cultured HSE
cells were incubated in the presence of absence of 2.5
μM RVL or recombinant VEGF antibody for 30 min,
after which B16M-CM or 10 ng/ml of recombinant
VEGF were added. Eight hours later, the supernatant
from the treated HSE cells were collected. IL-18 concen-
tration in serum from hepatic blood or in culture cell
media was detected using a competitive enzyme immu-
noassay (R&D Systems, Minneapolis, MN).
Immunohistochemical analysis of p65 nuclear
translocation
B16M cells (1 × 104 cells/well) were grown on 8 μm-
chamber glass slides. Cells were serum-starved for 24
h and treated with IL-18 (100 ng/ml) for 30, 60 and
120 min. In some experiments, cells received 2.5 μM
RVL 30 min prior to IL-18 treatment. Once treatment
time had finished, cells were fixed in 4% formaldehyde
(in PBS) for 30 min at room temperature and permea-
bilized in 1% SDS for 10 min. Non-specific binding
was blocked for 1 hour with 10% bovine serum in PBS
buffer. Cells were incubated with 1.5 μg/ml rabbit anti-
p65 polyclonal antibody (Santa Cruz Biotechnology
Inc., Santa Cruz, CA) for 1 h at room temperature.
Further wash steps removed unbound antibody prior
to the addition of the secondary Alexa 594 goat anti-
rabbit antibody. Images were acquired on a BD Path-
way™ Bioimager.
Western blot analysis of p65 in nuclear fractions
Subconfluent cultures of B16M cells were treated as
above described for 60 min. Then, they were harvested
and incubated in lysis buffer (10 mM HEPES (pH 7.9),
10 mM KCl, 0.1 mM EDTA, 0.1 mM DTT, 0.1% Noni-
det P-40 and 0.5 mM PMSF) for 20 minutes on ice. The
crude nuclei were collected by centrifugation, further
incubated in 20 mM HEPES (pH 7,9), 0.4 mM NaCl, 1
mM EDTA, 1 mM DTT, 1 mM phenylmethylsulfonyl
fluoride (PMSF) for 20 minutes on ice and clarified by
micro-centrifugation and frozen. Fifty micrograms of
nuclear extracts were resolved on 12% of SDS-PAGE
and p65 protein was analyzed by Western blot using
rabbit polyclonal antibody (Santa Cruz Biotechnology,
Santa Cruz, CA). Lamin-B expression was used as load-
ing control.
Western Blot analysis of VCAM-1
Freshly isolated HSE cells were seeded onto 24-well
plates for 24 hours. Then, they were cultured for 12
hours in the presence of basal medium, B16M-CM or 1
ng/ml IL-18. In some experiments, HSE cells received
2.5 μM RVL 30 min prior to B16M-CM or IL-18 treat-
ment. HSE cells were disrupted in 50 mM Tris (pH 7.5),
150 mM NaCl, 1% NP40, 0.5% deoxycholic acid, 0.1%
SDS, 2 mM EDTA, 10 mM NaF, 10 μg/ml leupeptin, 20
μg/ml aprotinin, and 1 mM PMSF. Then, 40 μg of
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protein from cell lysates were separated by 12% SDS-
PAGE followed by Western analysis using rat anti-
mouse VCAM-1 monoclonal antibody and b-tubulin
(both from Santa Cruz Biotechnology, Santa Cruz, CA)
and the appropriate secondary antibodies.
Blot was imaged using a Syngene G-Box gel imaging
system (Synoptics Ltd., Cambridge) and band density
analyzed using Gene Tools analysis software.
Measurement of H2O2 production from B16M cells in vitro
B16M cells were cultured in DMEM without phenol red
with 20 μmol/L 2’, 7’-dichlorofluorescein-diacetate
(DCFH-DA) as described [12]. H2O2 produced by incu-
bated cells oxidizes DCFH to the highly fluorescent
DCF so that fluorescence intensity is directly propor-
tional to the amount of H2O2 produced by the cells.
DCF fluorescence was recorded at 485/22-nm excitation
and 530/25-nm emission filters. Non-DCFH-DA-incu-
bated cells were used to determine basal autofluores-
cence. B16M cells were treated with 1 ng/ml IL-18, for
2 hours. In some experiments B16M cells were incu-
bated with 2.5 μM of RVL 30 minutes prior to IL-18
addition. H2O2 production per well was quantified in
arbitrary fluorescence units after subtracting basal
autofluorescence.
Proliferation assay
B16M cells were cultured overnight in DMEM plus 10%
FCS. Then, they were incubated for 72 hours in the pre-
sence of 0.1 ng/ml IL-18 supplemented with 0.5% FCS.
Control cells received the same culture medium without
the cytokine. In some experiments, 2.5 μM RVL was
added to control and IL-18-treated B16M cells. After 48
hours incubation, B16M cell proliferation was measured
using sulforhodamine 101 protein assay, as described
previously [15].
B16M cell adhesion assay to primary cultured hepatic
endothelial cells
B16M cells were labeled with 2’, 7’-bis-(2-carboxyethyl)-
5,6-carboxyfluoresceinacetoxymethylester solution
(Molecular Probes, Eugene, OR) and added to primary
culture of HSE cells (2 × 105 cells/well). Eight minutes
later, wells were washed three times with fresh medium.
The number of adhering cells was determined using a
quantitative method based on a previously described
fluorescence measurement system [14]. HSE were trea-
ted with B16M-CM for 6 hours prior to the addition of
B16M cells. In some experiments, HSE cells received 2.5
μM RVL or vehicle 30 minutes prior to B16M-CM. In
other experiments, B16M cells were pretreated with IL-
18 for 6 hours prior to the adhesion assay. In this case,
B16M cells received 2.5 μM RVL or vehicle 30 minutes
before IL-18.
Statistical analyses
Data were expressed as means ± SD. Statistical analysis
was performed by SPPS statistical software for Microsoft
Windows, release 6.0 (Professional Statistic, Chicago,
IL). Homogeneity of the variance was tested using the
Levene test. If the variances were homogeneous, data
were analyzed by using one-way ANOVA test with Bon-
ferroni’s correction for multiple comparisons when
more than two groups were analyzed. For data sets with
non-homogeneous variances, ANOVA test with Tam-
hane’s posthoc analysis was applied. Individual compari-
sons were made with Student’s two-tailed, unpaired t
test (program Statview 512; Abacus Concepts, Inc., for
Macintosh). The criterion for significance was P < 0.01
for all comparisons.
Results
Resveratrol inhibits hepatic seeding and growth of
metastatic melanoma cells
RVL given orally at 1 mg/kg from day 1 to 12 after
B16M cell injection reduced hepatic metastasis volume
by 75% as compared to control mice treated with vehi-
cle (Figure 1A-1E). Antimetastatic activities of RVL did
not involve any secondary effect that might compromise
animal survival. The same treatment schedule also sig-
nificantly (P < 0.01) decreased metastasis number by
50% (Figure 1E). Moreover, majority of metastases
developed in RVL-treated mice were on average signifi-
cantly smaller (by 60%) than those developed in vehicle-
treated mice. Therefore, B16M cells predominantly colo-
nized hepatic tissue through RVL-sensitive mechanisms.
Consistent with RVL-dependent decrease in hepatic
metastasis number, oral administration of the same daily
dose of RVL to animals during 5 days prior to cancer
cell injection, led to a statistically significant (P < 0.01)
hepatic retention decrease by 45% of luciferase-trans-
fected B16M cells (Figure 2.). Moreover, although anti-
metastatic effects of RVL affected 50% of metastases,
hepatic metastasis volume decreased by 75%, indicating
that either RVL-resistant metastasis had a slower growth
rate than RVL-sensitive ones, or that metastasis implan-
tation by RVL-resistant mechanism still had a RVL-sen-
sitive growth mechanism.
Consistent with previous reports [18], our histologic
study (Figure 1B and 1D) showed that hepatic mela-
noma metastases from vehicle-treated mice were predo-
minantly of sinusoidal-type, containing a rich network
of intratumoral microvessels supported by sinusoidal-
derived myofibroblasts; while a minority were of portal-
type, containing a lower density of intratumoral micro-
vessels, mainly supported by portal tract-derived myofi-
broblasts. Interestingly, RVL decreased by 80%
sinusoidal-type metastasis number, while it did not alter
the number of portal-type metastasis, indicating that
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RVL-sensitive metastases were of sinusoidal-type (E
Olaso, C Salado, B Arteta, A Lopategi, F Vidal-Vanaclo-
cha: Resveratrol inhibits the proangiogenic response of
hepatic sinusoidal cells to tumor-derived soluble factors
during liver metastasis by colon carcinoma, submitted).
Resveratrol inhibits hepatic secretion of IL-18 induced by
infiltrating metastatic melanoma cells
Previously, we reported that IL-18 increased in hepatic
venous blood over basal level during the sinusoidal
inflammation associated with liver-infiltrating cancer
cells [13,15]. A similar 5 day-RVL pretreatment schedule
as above also completely abrogated the augmentation of
IL-18 concentration in the hepatic blood obtained 18
hours after B16M cell injection into treated mice,
without affecting the physiological levels of this cytokine
in mice not injected with tumor cells (Figure 3A). In
order to discard that the increase in plasma IL-18 might
reflect a decreased hepatic metabolism of this cytokine
subsequent to the metastasis process [19], we next
determined the effect of RVL on IL-18 secretion from
tumor-activated hepatic sinusoidal cells. Primary cul-
tured HSE cells received either RVL or vehicle 30 min
prior to being treated with B16M-CM for 8 hours and
the level of IL-18 was measured in the supernatant by
ELISA. As shown in Figure 3B, RVL abolished the aug-
mentation of IL-18 concentration in B16-CM-treated
HSE cells, while it did not affect basal IL-18 concentra-
tions in the supernatant of untreated primary cultured
HSE cells.
Figure 1 Effect of resveratrol on hepatic metastasis development of intrasplenically-injected B16M. Mice were intrasplenically injected
with B16M cells and 1 mg/kg/day RVL was administered via intragastric tube, from day 1 to 12. A and C) Representative picture of livers from
vehicle- and RVL-treated mice obtained on the day 12 after cancer cell injection. Metastases are visible as black melanotic nodules. B and D)
Representative microscopic pictures of hepatic tissue sections from vehicle- and RVL-treated mouse livers. Tumor-affected hepatic tissue in blue
(H) and hepatic metastases in brown due to melanogenic cells (Met). Anti-smooth muscle-alpha antibodies were used to
immunohistochemically stain metastasis-associated stromal cells (in red). E) Metastatic volume and number in untreated and RVL-treated mice (n
= 10 per group), as percentage of liver occupied by metastases and number of foci per 100 mm3, respectively. Histograms represent average
values ± SD of 3 independent experiments. *Differences were statistically significant with respect to vehicle-treated mice (P < 0.01) according to
Bonferroni and post-hoc. ANOVA test.
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Previously, we showed that the pro-adhesive effect of
IL-18 on tumor-activated HSE cells was VEGF-depen-
dent [20]. Herein, we showed that anti-murine VEGF
antibody completely abrogated IL-18 secretion from
tumor-activated HSE cells and that RVL abolished IL-18
production from VEGF-activated HSE cells. Therefore,
RVL inhibited IL-18 secretion from tumor-activated
HSE cells through the specific inhibition of tumor-
derived VEGF on HSE (Figure 3B).
Resveratrol inhibits IL-18-induced VCAM-1 expression on
tumor-activated hepatic sinusoidal endothelium,
preventing microvascular adhesion of melanoma cells
Because IL-18 promotes the adhesion of B16 melanoma
cells to the hepatic microvascular endothelium via
VCAM-1-dependent mechanism [13,15], we next stu-
died the effect of RVL on the VCAM-1 expression level
in primary cultured hepatic endothelial cells given either
recombinant murine IL-18 or B16M-CM. As shown in
Figure 4A, pretreatment of HSE cells with RVL
abrogated VCAM-1 expression increase in HSE cells
given either IL-18 or B16M-CM. Consistently, RVL also
abolished the adhesion of B16M cells to HSE cells given
the same B16M-CM for 6 hours prior to adhesion
assays (Figure 4B).
Resveratrol inhibits adhesion- and proliferation-
stimulating effects of IL-18 on metastatic melanoma cells
As assessed by RT-PCR and flow cytometry, B16M cells
expressed IL-18 receptor alpha under basal culture con-
ditions [15,17]. Therefore, together with proinflamma-
tory effects of IL-18 on HSE cells, melanoma cell
function might also be affected by HSE-derived IL-18 in
the microenvironment of tumor-activated liver [13]. As
shown in Figure 5A, in vitro treatment with RVL
Figure 3 Effect of RVL on IL-18 secretion from tumor-activated
HSE cells in vivo and in vitro. A) IL-18 levels were determined in
serum samples obtained from suprahepatic vein blood on the 18th
hour after intrasplenic injection of 3 × 105 B16M cells. Some mice
received 1 mg/kg/day RVL via intragastic tube 5 days prior to
cancer cells injection. B) Primary cultured HSE cells were incubated
in the presence or absence of 2.5 μM RVL or recombinant VEGF
antibody for 30 min, and then with either B16M-CM or 10 ng/ml
recombinant murine VEGF. Eight hours later, the supernatants from
treated HSE cells were collected and IL-18 concentration
determined by ELISA. Data represent the average values ± SD of 3
independent experiments. *Differences were statistically significant
(P < 0.01) to respect to vehicle-treated mice, by Student’s two
tailed, unpaired t test.
Figure 2 Effect of resveratrol on melanoma cell retention in
the hepatic microvasculature of intrasplenically-injected B16M.
RVL was administrated via intragastric tube (1 mg/kg/day) during 5
days prior to 3 × 105 B16M-Luc cell intrasplenic injection. After 18
hours livers were removed and light production was measured as
described in Methods. Light emission values were expressed as
relative light units and the number of arrested B16M-Luc cells was
calculated on the basis of a standard curve relating specific relative
light units to B16M-Luc cell number. Data represent average values
± SD of two separate experiments. *Differences were statistically
significant (P < 0.01) to respect to vehicle-treated mice, by Student’s
two tailed, unpaired t test.
Salado et al. Journal of Translational Medicine 2011, 9:59
http://www.translational-medicine.com/content/9/1/59
Page 6 of 11
completely abrogated the hepatic microvascular arrest
augmentation induced in B16M cells given 1 ng/ml IL-
18 for 6 hours prior to their intrasplenic injection into
normal mice. The same treatment schedule with RVL
also prevented both B16M cell adhesion to primary cul-
tured HSE cells and B16M cell proliferation induced in
IL-18-pretreated B16M cells, without affecting these
functional activities in basal condition-cultured B16M
cells (Figure 5B and 5C). Because IL-18 regulates H2O2
production from B16M-CM-treated HSE cells [16], we
next studied the effect of RVL on H2O2 production
from IL-18-treated B16M cells. Interestingly, B16M cells
given 1 ng/ml IL-18 for 2 hours significantly (P < 0,01)
increased their H2O2 production. However, this cyto-
kine-induced oxidative reaction was completely neutra-
lized when B16M cells received RVL 30 min prior to IL-
18 (Figure 5D). Moreover, NF-kB activation is a known
pathway for attenuating cancer cell response to inflam-
matory mediators. Therefore, we examined the nuclear
translocation of p65, the transcriptionally active subunit
of NF-kB, in cultured B16M cells given recombinant
murine IL-18 (Figure 5E and 5F). First, as shown immu-
nofluorescence using an anti-p65 antibody (Figure 5E),
p65 remained cytosolic under basal conditions and no
change was observed when basal condition-cultured
cells received RVL. In contrast, a 60 min stimulation
with IL-18 (100 ng/mL) remarkably induced p65 trans-
location into the nucleus. P65 translocation persisted for
120 min (data not shown). However, addition of RVL to
IL-18-treated cells completely abrogated p65 transloca-
tion (Figure 5E). Second, similar results were obtained
when nuclear extracts from same experimental condi-
tions as above were analyzed for p65 protein expression
by Western blot (Figure 5F). Our data therefore indi-
cates that IL-18 activates NF-kB in B16M cells and that
RVL can efficiently inhibits this activation.
Discussion
We demonstrated that resveratrol prevented inflamma-
tion-dependent hepatic melanoma metastasis by inhibit-
ing both secretion of IL-18 from tumor-affected liver
and effects of hepatic IL-18 on melanoma cells. Daily
treatment with RVL significantly inhibited murine mela-
noma metastasis occurrence and development. Consis-
tent with these effects, oral administration of RVL
during 5 days prior to melanoma cell injection inhibited
both IL-18 augmentation in the hepatic blood and mela-
noma cell retention in the hepatic microvasculature of
melanoma cell-injected mice. This was further sup-
ported by in vitro experiments where RVL also inhibited
IL-18 secretion, VCAM-1 expression and melanoma cell
adhesion to tumor-activated HSE cells, three interrelated
events regulating the microvascular arrest of circulating
melanoma cells in the liver [2]. Our results also revealed
that RVL blocked both in vitro VLA-4-dependent
microvascular adhesion and proliferation in IL-18-trea-
ted melanoma cells, suggesting that RVL may also exert
its antimetastatic effect by preventing melanoma cell
response to endogenous hepatic IL-18. Not surprisingly,
both adhesion and proliferation were upregulated in IL-
18-treated melanoma cells via hydrogen peroxide-depen-
dent NF-kappaB activation, which was inhibited by RVL
in this tumor model. Therefore, our findings provide
evidence that RVL inhibited IL-18 secretion from
tumor-activated hepatic tissue, and subsequently, IL-18
effects on both host and cancer cells, which prevented
Figure 4 Effect of resveratrol on hepatic sinusoidal endothelial
cell response to tumor-derived factors. A) Representative
experiment on the effect of RVL and IL-18 on VCAM-1 protein
expression by tumor-activated HSE. Freshly isolated and primary
cultured murine HSE cells were incubated for 30 min with 2.5 μM
RVL or vehicle, and next with B16M-CM or 1 ng/ml IL-18 overnight.
Then, cell lysates were obtained and VCAM-1 protein was analyzed
by Western Blot. Quantification of VCAM-1 expression was
normalized to that of b-tubulin. B) Effect of RVL on B16M cell
adhesion to untreated and B16-CM treated HSE in vitro. Cultured
HSE were incubated with basal medium and B16M-CM for 6 hours.
In some wells, 2.5 μM RVL was added 30 minutes before B16M-CM.
Then, cell adhesion assay was performed as described in Methods.
The results are average values ± SD of 3 separated experiments,
each in triplicate (n = 9). Differences in the percentage of adhering
cells with respect to untreated HSE (*) or B16M-CM treated ESH (**)
were statistically significant (P < 0.01) by ANOVA and Bonferoni’s
post-hoc test.
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the inflammation-dependent metastasis class in the pro-
metastatic microenvironment created by tumor-induced
IL-18 in the liver.
Previous studies have already reported about anti-
metastatic effects of RVL on various rodent and human
solid tumors [5,6,21-23]. However, specific therapeutic
intervention sites of RVL along metastasis process are
still unclear. Herein, a hepatic melanoma metastasis
model–where majority of metastases are generated via
IL-18-dependent inflammatory mechanisms [13,15]–,
served to demonstrate that RVL specifically interferes
with inflammation-dependent metastases that develop in
the liver through oxidative stress-mediated mechanisms.
It has already been reported that RVL has beneficial
effects in pathogenic conditions of the liver that involve
an overproduction of inflammatory cytokines, such as
cholestasis [24], alcohol injury [25], and LPS [26]. More
importantly, it has also been shown that RVL suppresses
Figure 5 Effect of RVL on B16M cell response to IL-18. B16M cells, either untreated or pre-treated for 30 minutes with 2.5 μM RVL, were
incubated with 1 ng/ml IL-18 for different time periods. A) Effect of RVL on B16M-Luc cell retention in hepatic microvasculature. Mice were
intrasplenically-injected with either treated or untreated B16M-Luc cells and livers were analyzed after 18 hours. Light emission values were
determined as described in Methods. The number of arrested B16M-Luc cells was calculated on the basis of a standard curve relating specific
relative light units to B16M-Luc cell number. B) Effect of RVL on B16M cell adhesion to HSE. The percentage of adherent B16M cells was
determined as described in Material and Methods. C) Effect of RVL on B16M cell proliferation. B16M cell proliferation was analyzed by
sulforhodamine-101-based fluorometric assay. D) Effect of RVL on H2O2 production by B16M-Cells. H2O2 production was expressed as DCF
fluorescence values (in fluorescence arbitrary units). E and F) Inhibitory effect of Resveratrol on IL-18-induced NF-B activation. B16M cells were
serum-starved for 24 h and treated with IL-18 (100 ng/ml) from 30- to-120 min. In some experiments, cells received 2.5 μM RVL 30 min before
assays. Results shown are representative of the experiment after 60 min of treatment. NF-B nuclear translocation was detected by
immunofluorescent staining with anti p-65 antibody. (E). Western analysis was also performed with anti-p65 antibody and Lamin B as a loading
control for the nuclear fraction (F). Every assay was done in triplicate and repeated three times. Data represent average values ± SD. *Differences
were statistically significant with respect to cells in basal medium (P < 0.01) according ANOVA test.
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oxidative stress and inflammatory response in diethylni-
trosamine-initiated rat hepatocarcinogenesis [5,6]. How-
ever, at the moment RVL has not yet been reported as a
potential inhibitor of prometastatic effects of hepatic
inflammation created in the liver microenvironment by
tumor-induced IL-18.
IL-18 is a proinflammatory cytokine that increases in
the blood of the majority of cancer patients and that has
been associated with disease progression and, in some
cancer types, even with metastatic recurrence, poor clin-
ical outcome and survival [17]. While recombinant IL-
18 has very limited therapeutic activity as a single agent
in patients with metastatic melanoma [27], preclinical
studies have shown that IL-18 binding protein inhibits
hepatic and lung metastases in murine models [15,28].
This is further supported by studies revealing that IL-
18-dependent mechanisms promote immune escape
[29], microvascular adherence [13], resistance to UVB-
induced apoptosis [30], and angiogenesis [18,31]. There-
fore, the fact that RVL completely abrogated the
increase of hepatic blood IL-18 induced by tumor-
derived factors suggests the potential use of RVL as a
hepatic metastasis chemopreventive agent in cancer
patients at high risk of hepatic metastasis, such as those
suffering from a malignant uveal melanoma.
IL-18 is also a major IFN-gamma-inducing factor and
both IL-18 and IFN-gamma act together in the host
response to infection, but also in the pathogenesis of
acute hepatic injury [32]. In our model, abrogation of
tumor-induced hepatic IL-18 did not involve any
decrease of IFN-gamma level, which also significantly
increased in the hepatic blood of same animals (data
not shown). This suggests that IL-18-independent path-
ways were also operating in the induction of IFN-
gamma secretion during tumor metastasis development
in this model.
Previously, we have reported that liver-infiltrating
B16M cells activated their adhesion to HSE cells
through a sequential process involving TNF-alpha-
dependent IL-1beta, which in turn induced IL-18 to up-
regulate VCAM-1 via H2O2 [13,16]. The pivotal position
of IL-18-induced H2O2 was further supported by the
fact that incubation of HSE cells with nontoxic concen-
trations of H2O2 directly enhanced VCAM-1-dependent
B16M cell adhesion in vitro without pro-inflammatory
cytokine mediation, which emphasizes the key role of
oxidative stress in the pathogenesis of IL-18-dependent
hepatic metastasis [16]. Our current results show that
RVL abolished H2O2 production from IL-18-treated
melanoma cells. This has implications in several
mechanisms: first, because it prevents oxidative stress-
dependent VLA-4 integrin activation in melanoma cells;
second, because it prevents nuclear translocation of
NFkappaB, which is oxidative stress-dependent as well;
and third, because it blocks IL-18 receptor-expressing
melanoma cell subpopulation enlargement [17].
RVL also decreased metastasis number by 50%, sug-
gesting that hepatic colonization of this murine mela-
noma occurred via RVL-sensitive and RVL-resistant
mechanisms. However, hepatic metastasis volume
decreased by 75%, indicating that either RVL-resistant
metastases had a slower growth rate than RVL-sensitive
ones, or that most of metastasis implantation by RVL-
resistant mechanism still had a RVL-sensitive growth
mechanism. According to our results, RVL-dependent
metastatic growth inhibition it may depend in part on
direct anti-proliferative effects of RVL on IL-18-depen-
dent melanoma cells. It also may be due to a decrease
of angiogenic parameters in hepatic B16M metastases
from RVL-treated mice (E Olaso, C Salado, B Arteta, A
Lopategi, F Vidal-Vanaclocha: Resveratrol inhibits the
proangiogenic response of hepatic sinusoidal cells to
tumor-derived soluble factors during liver metastasis by
colon carcinoma, submitted). In this case, the mechan-
ism appears to depend on the remarkable inhibitory
effect of RVL on the proangiogenic effects of tumor-
activated hepatic myofibroblasts [18].
In summary, this study uncovers multiple therapeutic
intervention sites for RVL in the inflammatory microen-
vironment of tumor-activated hepatic sinusoids occur-
ring prior to metastasis development (Figure 6). First,
RVL inhibited hepatic secretion of IL-18 induced by
liver-infiltrating melanoma cells; second, it prevented
IL-18-dependent VCAM-1 expression on the hepatic
microvasculature which decreased by 50% the microvas-
cular retention of melanoma cells in the liver; and third,
it prevented melanoma cell responses to hepatic IL-18,
further affecting VLA-4-dependent melanoma cell adhe-
sion and proliferation. Therefore, by acting on host and
tumor-dependent responses to IL-18, RVL very effi-
ciently inhibited cancer cell arrest and growth initiation
in the tumor microenvironment. Thus, this study
uncovers a pathophysiological mechanism accounting
for the metastasis-chemoprevention effect of a natural
product in the liver.
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